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Prevalence of Brain Metastases Immediately before
Prophylactic Cranial Irradiation in Limited Disease Small
Cell Lung Cancer Patients with Complete Remission to
Chemoradiotherapy: A Single Institution Experience
Farkhat Manapov, MD,* Gunther Klautke, MD,* and Rainer Fietkau, MD*†
This single-center study investigated the prevalence of brain metas-
tases immediately before prophylactic cranial irradiation in 40
consecutive limited disease small cell lung cancer complete re-
sponders to chemoradiotherapy and revealed that 13/40 (32.5%;
95% confidence interval: 18–47%) patients suffer relapse with brain
metastases and show a significantly worse prognosis than those
without detected brain metastases.
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The central nervous system is a favorable site of failure forpatients with small cell lung cancer (SCLC).1,2 Asymp-
tomatic brain metastases (BM) have been detected in 24% of
all SCLC patients evaluated by contrast-enhanced cranial
magnetic resonance imaging (MRI) at initial diagnosis.3 Cur-
rently, concurrent chemoradiotherapy (CRT) followed by
four courses of consolidation chemotherapy (CT) is the stan-
dard treatment for limited disease (LD) SCLC and all LD
SCLC patients exhibiting a complete remission (CR) should
be indicated to prophylactic cranial irradiation (PCI).4 A
meta-analysis has shown that PCI significantly reduces the
incidence of BM and improves disease-free survival and overall
survival in complete responders, regardless of whether they
receive CT with or without thoracic irradiation.5 Previous
studies assessing the rationales for timing of PCI have also
shown that early PCI is more effective than late PCI in
preventing overt BM of SCLC.5–7 However, MRI-based in-
formation about the prevalence of BM immediately before
PCI in complete responders to CRT is lacking. Theoretically,
this population could contain patients with occult brain BM.8
To address this question, we performed a second contrast-
enhanced cranial MRI in 40 consecutive LD SCLC complete
responders to CRT immediately before PCI. A descriptive
analysis of our findings regarding the prevalence of pre-PCI
detected BM and their effect on prognosis are included in this
report.
PATIENTS AND METHODS
Patient Eligibility
Between 1997 and 2006, 105 patients with histologi-
cally confirmed LD SCLC received concurrent or sequential
CRT at our hospital. All patients consented to participate in
the study. Initial staging included bronchoscopy with biopsy,
computer tomography scans of the chest and abdomen, bone
scintigraphy, and first contrast-enhanced cranial MRI. Re-
evaluation after completion of CRT included bronchoscopy
with biopsy, computer tomography scans of the chest and
abdomen, and bone scintigraphy. Patients with a tumor-free
biopsy were defined as complete responders in cases where
staging did not demonstrate any signs of tumor. Forty com-
plete responders were identified. All of these patients re-
ceived a second contrast-enhanced cranial MRI immediately
before PCI and formed a population of interest (Figure 1).
CRT of LD SCLC
Sequential CRT (six cycles of CT followed by thoracic
irradiation) was the standard treatment for LD SCLC up to
2000. Since 2000, it has been replaced by concurrent CRT
(thoracic irradiation simultaneous with the first and second
cycles of CT followed by four cycles of consolidation CT).
Thirty of the overall group of 105 patients received a com-
bination of cisplatin and irinotecan according to Rostock’s
phase I study protocol.9 About 70/105 patients received other
combinations such as carboplatin, etoposide and vincristine;
carboplatin and etoposide; carboplatin and vincristine or
nonplatinum-based combinations. Twenty-one (70%) of the
30 patients treated with cisplatin and irinotecan achieved CR
compared with 19/75 (25.3%) of those treated with other
combinations (p  0.001).
Thoracic irradiation was delivered with megavoltage
equipment (8–10 MV) using a multiple field technique.
Three-dimensional treatment planning was performed. All
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patients were irradiated 5 days a week (daily fractions of 1.8
Gy to a total dose of 54 Gy).
Contrast-Enhanced Cranial MRI
Investigation was performed at initial staging and
within a week of diagnosis of CR to CRT with a 1.5 Tesla
system according to a standard protocol (T1 spin echo trans-
versal  coronar [saggital optional], TR 700 milliseconds,
slice thickness 5 mm; MR contrast medium: gadolinium
DTPA at a dose of 0.1 mmol/kg).
Treatment of pre-PCI Detected BM
BM were detected in 13 patients immediately before
PCI. Treatment consisted of either whole-brain radiation
alone (WBR) with 3.0 Gy fractions to a total dose of 30 Gy
(n  6) or WBR with 2.0 Gy fractions to a total dose of 40
Gy (n  6) as a part of second-line CRT with topotecan. No
treatment was administered in one case because the patient
refused treatment. Topotecan was administered according to
Rostock’s phase II study protocol.10 There were no criteria
determining which one of the two treatment regimens was to
be used.
PCI
PCI (1.8 Gy fractions to a total dose of 36.0 Gy) was
performed in 20 (74%) of the 27 in whom no BM after
completion of CRT were detected. The other seven patients
(26%) declined PCI treatment.
Statistics
This descriptive analysis describes the prevalence of
BM in LD SCLC complete responders to CRT, as determined
by a second post-CRT contrast-enhanced cranial MRI, and
the outcome of complete responders with and without pre-
PCI detected BM. One must be aware that treatment decision-
making was guided by the results of this second cranial MRI.
The cut-off date for evaluation was November 1 2006. The
median follow-up period was 16 months (range: 2–49
months). Using SPSS 14.0 software, Kaplan-Meier survival
was calculated relative to the date of LD-SCLC diagnosis and
the date of second cranial MRI to the death of the patient or
to the last follow-up, respectively. All p values are derived
from two-sided statistical tests; p  0.05 was considered to
be significant.
RESULTS
Prevalence of BM Immediately before PCI in
LD SCLC Complete Responders to CRT
The 40 (38%) out of 105 LD SCLC patients who
achieved CR to CRT received a second contrast-enhanced
cranial MRI immediately before PCI (Table 1). The mean
FIGURE 1. Patient selection according to the
outcome of CRT and the findings of the sec-
ond cranial MRI performed immediately before
a planned PCI.
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time between LD SCLC diagnosis and the second cranial
MRI was 7 months (range: 4–10 months). All 40 complete
responders were neurologically asymptomatic after comple-
tion of CRT.
The second cranial MRI revealed BM in 13/40 patients
(32.5%; 95% confidence interval: 18–47%), two (5%) of
whom have developed neurologic symptoms within a week
of diagnosis of CR to CRT. The mean time between
completion of systemic treatment and second cranial MRI
was not different in the BM-positive (28 days) and BM-
negative patients (26 days). Additionally, the prevalence of
BM was not different in patients treated with (6/21; 28.6%) or
without (7/19; 36.8%; p  0.577) irinotecan-containing com-
binations.
Prognoses of LD SCLC Complete Responders
with and without pre-PCI Detected BM
In the 40 complete responders, median survival (MS)
from the time of LD SCLC diagnosis was 20 months (95%
CI, 11.6–28.3), and MS from second cranial MRI to the last
follow-up or death was 13 (95% CI, 7.6–18.3). The 1- and
2-year survival rates after LD SCLC diagnosis were 81.4 
6.3% and 42.1  9.2%, respectively; those after second cranial
MRI were 54.0  8.8% and 22.9  9.2%, respectively.
In the 13 complete responders with pre-PCI detected
BM MS from the time of LD SCLC diagnosis was 14 months
(95% CI, range: 10.6–17.3), and that from the time of second
cranial MRI was 6.5 months (95% CI, 1.6–11.3). One-year
survival after LD SCLC diagnosis was 58.7  14.2% versus
17.3  11.1% after second cranial MRI. Eleven (84.6%) of
the 13 patients developed neurologic symptoms that persisted
until death or until the end of follow-up, indicating a pro-
gression in the brain. Six of the 13 (46.2%) were treated with
WBR alone, and another six (46.2%) received WBR as a part
of second-line CRT with topotecan (continuous infusion at a
dose of 0.4 mg/m2/d). The 13th patient (7.6%), who declined
treatment, died 1 month after the second cranial MRI. Median
and 1-year survival after second cranial MRI in the group
treated with WBR alone was four months (95% CI, range:
0–8) and 16.7  15.2%, respectively, compared with 10
months (95% CI, range: 0–25.6) and 22.2  19.2% in the
group treated with second-line CRT (p  0.02). Extracranial
progression, including local recurrence and/or distant metas-
tases, was subsequently diagnosed in 7/13 (53.8%) patients
(Table 2).
In the 27 complete responders without pre-PCI detected
BM, MS after LD SCLC diagnosis was 26 months (95% CI,
range: 20.9–31.0), and that after second cranial MRI was 22
months (95% CI, range: 13.1–30.8). The 1- and 2-year
survival rates were 92  5.4% and 61.1  11.3% and 74.2 
9.2% and 34.6 13% after diagnosis and after second cranial
MRI, respectively. These values were significantly better than
those in the 13 complete responders with pre-PCI detected
BM (p  0.0001). PCI was performed in 20 (74%) of the
BM-negative patients, 4 (20%), of whom developed BM 6,
15, 15, and 21 months after treatment (the brain was the only
a site of failure in one case). Seven complete responders
(26%) without pre-PCI detected BM did not receive PCI; one
(14%) of these patients developed BM 10 months later.
Extracranial progression was subsequently diagnosed in 12
(44.4%) of the 27 BM-negative patients (Table 2).
DISCUSSION
Most national guidelines recommend contrast-en-
hanced cranial MRI in the initial staging of SCLC,3,11 but not
immediately before PCI. In the present study, occult BM
were detected by pre-PCI second contrast-enhanced cranial
MRI in 32.5% (95% confidence interval: 18–47%) of LD
SCLC complete responders to concurrent or sequential CRT.
Moreover, complete responders with pre-PCI detected BM
had a significantly worse prognosis than those without de-
tected BM.
TABLE 1. Patient Characteristics
Characteristic
No. of
Patients
LD SCLC patients 105
LD SCLC patients with CR to CRT 40
Female 17
Median age, yr 63
Range 44–83
Male 23
Median age, yr 61
Range 39–79
LD SCLC complete responders treated with
Concurrent CRT 21
Sequential CRT 19
Time from diagnosis of LD SCLC to second
cranial MRI immediately before PCI, mo
7
Range 4–10
LD SCLC complete responders with immediately
before PCI detected BM
13
After concurrent CRT 6
After sequential CRT 7
Symptomatic in brain 2
Asymptomatic in brain 11
LD SCLC complete responders without
immediately before PCI detected BM
27
After concurrent CRT 15
After sequential CRT 12
LD SCLC complete responders with
immediately before PCI detected BM
Treated with
WBR 6
WBR  CT with Topotecan 6
Untreated 1
LD SCLC complete responders without
immediately before PCI detected BM
Subjected to PCI 20
Not subjected to PCI 7
CR, complete remission; CRT, chemoradiation; CT, chemotherapy; LD, limited
disease; MRI, magnetic resonance imaging; PCI, prophylactic cranial irradiation;
SCLC, small cell lung cancer; WBR, whole brain irradiation.
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The present results are in agreement with previous
studies demonstrating an important role of timing of PCI for
BM-free survival, showing a steep dose-response curve after
early PCI, but not after late PCI and suggesting that the loss
of the steep dose-response curve occurs due to the develop-
ment of overt BM from subclinical disease.6,7 Indeed, in our
study, PCI was applied late in the treatment protocol that can
influence the prevalence of BM, as was already shown by
Auperin et al.5 Based on the previous and present results, we
advise performing a second contrast-enhanced cranial MRI if
PCI will delayed more than four months after the start of CRT
because overt BM may develop from subclinical disease
during this time. In addition, the second cranial MRI can help
to distinguish complete responders who already have occult
BM from those who should receive prophylactic PCI.
The present study also provides evidence that CT a key
part of multimodality treatment concept was not enough to
prevent occult BM in complete responders; however, the pro-
longed (up to 10 months) and nonstandardized (with presum-
ably different effectiveness) induction phase can be consid-
ered as a most plausible explanation for this phenomenon.
Nevertheless, the present data are in accordance with previ-
ous report that demonstrated unexpectedly high rate of BM as
the first site of failure in LD SCLC patients treated with
concurrent CRT and with the finding of evidently lower
response rate of asymptomatic BM from SCLC to CT com-
pared with the systemic response rate.12,13 Therefore, it is also
reasonable to discuss the possibility to incorporate PCI into
the treatment of LD SCLC before the completion of CRT.
This consideration is supported by previous investigations
indicating that PCI is less effective when performed later.5–7
However, the possibility that performing PCI simultaneous
with CT might increase the neurotoxicity rate must also be
considered, that is, Ball and Matthews14 found a 26% inci-
dence of neurotoxicity in studies where the PCI and CT were
given concomitantly, versus 12% where they were not. If so,
this may compromise the application of systemic treatment.
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TABLE 2. Survival, Intracranial Relapse, and Extracranial Progress by LD SCLC Complete Responders to CRT
LD SCLC Complete Responders
without Immediately before PCI
Detected BM (n  27)
LD SCLC Complete Responders
with Immediately before PCI
Detected BM (n  13)
MS from diagnosis of LD SCLC (mo) 26 (95 CI, 20.9–31.0) 14 (95 CI, 10.6–17.3)
1-yr survival from diagnosis of LD SCLC (%) 92  5.4 58.7  14.2
2-yr survival from diagnosis of LD SCLC (%) 61.1  11.3 Not achieved
MS from date of second cranial MRI before PCI (mo) 22 (95 CI, 13.1–30.8) 6.5 (95 CI, 1.6–11.3)
1-yr survival from date of second cranial MRI before PCI (%) 74.2  9.3 17.3  11.1
2-yr-survival from date of second cranial MRI before PCI (%) 34.6  13 Not achieved
Intracranial relapse 5/27 (18.5%) 11/13 (84.6%)
Extracranial progress 12/27 (44.4%) 7/13 (53.8%)
Second-line CT or CRT 7/27 (25.9%) 6/13 (46.1%)
dead at the end of follow-up period 12/27 (44.4%) 11/13 (84.6%)
CR, complete remission; CRT, chemoradiation; CT, chemotherapy; LD, limited disease; MRI, magnetic resonance imaging; MS, median survival; PCI, prophylactic cranial
irradiation; SCLC, small cell lung cancer; WBR, whole brain irradiation.
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